GLP1.Guide Staff

Scouring sources for information on GLP1 Agonist drugs, so you don't have to.

🗞️ Looking to keep up with GLP1s? We've moved to Substack

GLP1.Guide is now best viewed on Substack: Read the rest on Substack New information is posted there first, and in the future this site will be converted to redirect directly to Substack. Thanks for supporting GLP1.guide, we'll see you over on Substack!

Oral GLP1s you've probably never heard of

Most people have heard of Mounjaro, Zepbound, Wegovy, Ozempic and Rybelsus by now. The words “VK2735” or “Orforglipron” mean nothing to most people, though now almost everyone is familiar with GLP1s as a class of drugs (at the very least the effects). There are some obscure GLP1s under development that

Last week in GLP1 (2025/10/13)

We’ve gathered some key stories from the GLP1 ecosystem in the last week you might have missed: 🔎 GLP1 interfering with medical imaging? 💚 More research on GLP1’s benefits for stopping substance & alcohol Abuse 📑 Ketones + GLP1s prevent muscle loss (in mice) 🚨 Semaglutide Withdrawal and it’s effects on Type

Last week in GLP1 (2025/10/06)

We’ve gathered some key stories from the GLP1 ecosystem in the last week you might have missed: 💼 Costco is now selling heavily discounted GLP1s 🦘 Buzz in Australia around GLP1s as a public benefit 💊 Excitement is growing around oral GLP1s 🏫 Harvard doctor doubles down on benefits of GLP1 for inflammation

Last week in GLP1 (2025/09/22)

Here’s what happened last week in the GLP1 ecosystem: 📊 Study: Wegovy pill shows 16.6% weight loss 📢 Eli Lilly says Orforglipron is even better than the Wegovy pill 📺 GLP1s in patch form? Not yet 📑 GLP1s could reduce all-cause mortality by up to 6% by 2045 ❓Bariatric surgery more effective

A new study on GLP1s eye risk

One of the biggest emerging risks of using GLP1s has been the link between GLP1s and vision loss — whether via NAION or macular degeneration. We’ve covered this before: The link between Semaglutide & vision loss (NAION)How deep is the link between GLP1s and possible vision loss? We examine

Last week in GLP1 (2025/09/15)

Here’s what happened last week in the GLP1 ecosystem: 🧑‍⚖️ Lawsuits over the negative side effects of GLP1s 🌐 The WHO is building a guideline for GLP1 use and requesting comments 🎭 Celebrity endorsements continue: Andy Cohen reveals use of GLP1s for weight management 🚨 GLP1 is now being used in SMS scams

Massive GLP1 use in Silicon Valley survey

We mostly hear of increased adoption of GLP1s in the mainstream — entertainers and public figures being quizzed on whether they use it or not, spectacular transformations for patients who have found a GLP1 that works for them, etc. Silicon Valley and those that like to experiment or “bio-hack” were very

An under-reported negative side effect: CVS

Keeping track of negative side effects of GLP1s is just as important (if not more important) than keeping track of positive side effects. Cyclic Vomiting Syndrome is a *rare* negative side effect that doesn’t come up in the research very often, but after hearing anecdotal reports of this side

Last week in GLP1 (2025/09/08)

Here’s what happened last week in the GLP1 ecosystem: 🌎 World Health Organization (WHO) adds GLP1 to essential medicines list (for diabetes) 🏛️ FDA Creates 'Green List' of GLP-1 Drug Ingredients Approved for Entry in the U.S. 🧑‍⚖️ CVS Caremark gets sued for stopping coverage of GLP1s 📰 GLP-1 Receptor

Last week in GLP1 (2025/09/01)

Here’s what happened last week in the GLP1 ecosystem: 📑 Orforglipron Phase 3 trial results landed 📢 TEVA Pharmaceuticals announced FDA approval for weight loss with Liraglutide 🎤 Meghan Trainor has been in the news after a GLP1 transformation 🎾 Serena Williams has shared her GLP1 story Go deeper, read more Here are

drug:orforglipron

A high quality GLP1 pill: once-daily Orforglipron

We take a look at the most recent set of results from Orforglipron, the oral GLP1 from Eli Lilly

drug:cagrisema

CagriSema underperforms in trial

We take a look at the recent results for CagriSema, and see how it tracks against other GLP1s

chemical:semaglutide

Kidney injuries on Ozempic

Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.

drug:mounjaro

Mounjaro vs Trulicity in a clinical trial

Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.

politics

Medicare/Medicaid might pay for GLP1s again

GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.

drug:phentermine

Boosting GLP1s with Phentermine

Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?

chemical:semaglutide

Another GLP1 Generic launch: India's Dr Reddy's

Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?

company:hims

Hims will sell generic Semaglutide in 2026

Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?

company:novo-nordisk

Novo Nordisk is introducing a higher dose of Wegovy

Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.

company:weight-watchers

Novo's expanding collaboration with Weight Watchers

Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299

drug:wegovy

Less for Less: CVS drops Zepbound for Wegovy

CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).

includes:study

If GLP1 is so great, why don't people stick with it?

Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.

category:news

A glowing endorsement of GLP1s by cardiologists

Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.

category:risks

A new risk? Macular Degeneration

We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.